GLP-1 receptor agonists × blood pressure

TrialClinical journal of the American Society of Nephrology : CJASN2026

Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.

Hiddo J L Heerspink et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 101 people · 2026

Randomised comparison

Probably lowered body weight & composition

−9.10−11.0 to −7.20

As reported

difference −9.1, 95% CI −11.0 to −7.20

Randomised comparison

Probably lowered blood pressure

−0.90−1.60 to −0.10

As reported

difference −0.9, 95% CI −1.60 to −0.10

Two numbers in the abstract

the abstract, start to end

weight, lean body mass, and fat mass by -9.1 (95% confidence interval [CI],

extracellular water and systolic BP by -0.9 (95% CI, -1.6 to -0.1) L and

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−9.1−11.0 to −7.20
Blood pressure
−0.9−1.60 to −0.10
GLP-1 receptor agonistsBody weight & compositionBlood pressure

GLP-1 receptor agonists × blood pressurehelps?mixed

unlikelylikely
0.500.50 without it

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

1 paper cites it

2026
this papercites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 42308057